Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 4309 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Merck vaccine prevents STDs in adolescents

The investigational vaccine, Gardasil is designed to prevent infection from four common quadrivalent human papillomavirus (HPV) types and related cervical cancer, cervical pre-cancers and genital warts. The trial

Bionaut and Cancer Institute form collaboration

The National Cancer Institute (NCI) and Bionaut will also collaborate to identify new biomarkers in tumor cells that are affected by Bionaut’s lead cancer compounds. Bionaut’s compounds will

Chiron and Enanta sign hepatitis drug deal

Under the arrangement Enanta has been granted a non-exclusive license to Chiron’s hepatitis C virus (HCV) technology to further enable the research and development of HCV therapeutics. Enanta

AlphaRx and Basin enter marketing collaboration

Under the agreement, Basin Industrial, a wholly-owned subsidiary of Hong Kong based Advance Pharmaceutical Co (APC), will fund the manufacturing and marketing of products in China, Hong Kong,

Glaxo expands resources though new research unit

The “Centre of Excellence for External Drug Discovery” (CEEDD) will work in partnership with biotechnology companies, small and mid-sized pharmaceutical companies and academic institutions to deliver compounds with

Pro-Pharmaceuticals begins phase II cancer trial

The study is in metastatic colorectal cancer patients who have disease progression after receiving standard chemotherapeutic regimens and is the result of a collaboration between Pro-Pharmaceuticals and the

Ziopharm progressing with phase I cancer trials

ZIO-101 is the first compound from a family of novel organic arsenics. Preclinical evidence suggests that because of the potential for much higher doses and pharmacokinetic differences between

Santaris begins multi-center leukemia trial

The trial is an escalating, repeated dose study of this new investigational drug in chronic lymphocytic leukemia (CLL) patients who have failed or no longer respond to chemotherapy.